Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Biotechnology Merger to Spur Development of a Gene Therapy Approach for Treatment of Congestive Heart Failure

By BiotechDaily International staff writers
Posted on 24 Aug 2014
ADVERTISEMENT
SARTORIUS AG
Rapid improvement in the treatment of congestive heart failure (CHF) is expected following the acquisition of InoCard, a German early-stage biotechnology company by uniQure, a Dutch leader in the field of gene therapy.

CHF is characterized by the inability of the cardiac muscle to provide sufficient circulatory support both at rest and during exercise. It is a rapidly progressing disease affecting some 26 million people worldwide, with patients suffering from severe heart failure facing a five-year mortality rate of over 50%.

Currently there is no cure for CHF, but this may change following the purchase of InoCard GmbH (Heidelberg, Germany) by uniQure N.V. (Amsterdam, The Netherlands). InoCard GmbH, a privately held early-stage biotechnology company, has developed an innovative AAV (adeno-associated virus)-based gene therapy approach for the long-term treatment of CHF, targeting the calcium-binding protein S100A1. The Dutch company uniQure has developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders.

The target of the new partnership is to develop a commercially viable gene therapy approach to restore S100A1 levels in CHF patients. Research has shown that administration of S100A1 to CHF patients has beneficial effects on contractile force, growth control of heart muscle cells, and rhythm stability of the heart and is also able to adapt the heart's energy supply to increased cardiac output. In a porcine heart failure model, treatment with InoCard's gene therapy AAV-S100A1 demonstrated a 12-month survival rate of 90%.

"The acquisition of InoCard is a further demonstration of uniQure's strategy to access the best early-stage programs in our industry and accelerate their development by the application of our proven modular platform," said Jörn Aldag, CEO of uniQure. There is strong scientific rationale that addressing calcium dysregulation leads to an astounding effect in congestive heart failure. We believe that together we will deliver the best-in-class treatment for congestive heart failure."

"Despite the continuously growing prevalence of CHF, there have been no therapeutic innovations in decades. InoCard has successfully laid the basis for the development of a long-term, causative treatment of this devastating disease," said Dr. Patrick Most, founder of InoCard. "We believe that combining our promising S100A1 therapy with uniQure's capabilities in innovating safe and effective gene therapies has the potential to transform the treatment of cardiovascular diseases."

Related Links:

uniQure N.V.



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.